299 related articles for article (PubMed ID: 16036064)
1. Mechanism of action of bisphosphonates.
Reszka AA; Rodan GA
Curr Osteoporos Rep; 2003 Sep; 1(2):45-52. PubMed ID: 16036064
[TBL] [Abstract][Full Text] [Related]
2. [Basic Studies on the Mechanism, Prevention, and Treatment of Osteonecrosis of the Jaw Induced by Bisphosphonates].
Endo Y; Funayama H; Yamaguchi K; Monma Y; Yu Z; Deng X; Oizumi T; Shikama Y; Tanaka Y; Okada S; Kim S; Kiyama T; Bando K; Shima K; Suzuki H; Takahashi T
Yakugaku Zasshi; 2020; 140(1):63-79. PubMed ID: 31902887
[TBL] [Abstract][Full Text] [Related]
3. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
Luckman SP; Hughes DE; Coxon FP; Graham R; Russell G; Rogers MJ
J Bone Miner Res; 1998 Apr; 13(4):581-9. PubMed ID: 9556058
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates: preclinical aspects and use in osteoporosis.
Fleisch HA
Ann Med; 1997 Feb; 29(1):55-62. PubMed ID: 9073324
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonate therapy.
Licata AA
Am J Med Sci; 1997 Jan; 313(1):17-22. PubMed ID: 9001162
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors.
Van Beek ER; Löwik CW; Papapoulos SE
Bone; 2002 Jan; 30(1):64-70. PubMed ID: 11792566
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of phosphate transporters ameliorates the inflammatory and necrotic side effects of the nitrogen-containing bisphosphonate zoledronate in mice.
Okada S; Kiyama T; Sato E; Tanaka Y; Oizumi T; Kuroishi T; Takahashi T; Sasaki K; Sugawara S; Endo Y
Tohoku J Exp Med; 2013 Oct; 231(2):145-58. PubMed ID: 24140868
[TBL] [Abstract][Full Text] [Related]
8. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
van beek E; Löwik C; van der Pluijm G; Papapoulos S
J Bone Miner Res; 1999 May; 14(5):722-9. PubMed ID: 10320520
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
10. [Bisphosphonates: the molecular targets and mechanisms of action].
Wada S; Kamiya S; Ono K
Clin Calcium; 2005 May; 15(5):819-24. PubMed ID: 15876745
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
[TBL] [Abstract][Full Text] [Related]
12. Use of bisphosphonates in cancer patients.
Body JJ; Coleman RE; Piccart M
Cancer Treat Rev; 1996 Jul; 22(4):265-87. PubMed ID: 9025784
[No Abstract] [Full Text] [Related]
13. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis.
Halasy-Nagy JM; Rodan GA; Reszka AA
Bone; 2001 Dec; 29(6):553-9. PubMed ID: 11728926
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates: from the laboratory to the clinic and back again.
Russell RG; Rogers MJ
Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
[TBL] [Abstract][Full Text] [Related]
15. New insights into the molecular mechanisms of action of bisphosphonates.
Rogers MJ
Curr Pharm Des; 2003; 9(32):2643-58. PubMed ID: 14529538
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonate mechanism of action.
Reszka AA; Rodan GA
Curr Rheumatol Rep; 2003 Feb; 5(1):65-74. PubMed ID: 12590887
[TBL] [Abstract][Full Text] [Related]
17. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates.
van Beek ER; Cohen LH; Leroy IM; Ebetino FH; Löwik CW; Papapoulos SE
Bone; 2003 Nov; 33(5):805-11. PubMed ID: 14623056
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates and breast carcinoma.
Lipton A
Cancer; 1997 Oct; 80(8 Suppl):1668-73. PubMed ID: 9362434
[TBL] [Abstract][Full Text] [Related]
19. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates in prostate carcinoma.
Adami S
Cancer; 1997 Oct; 80(8 Suppl):1674-9. PubMed ID: 9362435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
